Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Merck (MRK - Analyst Report) recently announced its decision to halt a phase III study with its HIV drug Isentress based on the recommendation of an independent Data Monitoring Committee. The phase III study was being conducted to investigate the safety and efficacy of a once-daily dosage of Isentress in treatment-naïve adult HIV patients.

Isentress is currently approved in a twice-daily dosage regimen for the treatment of HIV in treatment-naïve and treatment-experienced adults in combination with other antiretroviral therapies.

The phase III study compared the once-daily (800 mg once daily) dosing regimen of Isentress with the currently approved twice-daily (400 mg twice daily) dosing regimen. While the once-daily dosage helped achieve viral suppression in more than 80% of the patients, it failed to show non-inferiority to the twice-daily treatment regimen.

Results showed that after 48 weeks, 83.2% of the patients in the once-daily arm achieved undetectable viral levels compared to 88.9% in the twice-daily arm. Full results from this study will be presented at a scientific meeting next year.

The results are disappointing as a once-daily treatment regimen would have been more convenient for HIV patients and would have helped reduce the chance of patients missing dosages.

Merck’s Isentress is the first integrase inhibitor to have gained approval. Isentress is currently approved in more than 90 countries across the world and the product is on track to become a blockbuster with sales during the first nine months of 2010 coming in at $777 million.

However, competition is fast catching up with companies like Gilead (GILD - Analyst Report), Pfizer/GlaxoSmithKline (PFE - Analyst Report)/(GSK - Analyst Report) working on bringing their integrase inhibitors to market.

Neutral on Merck

We currently have a Neutral recommendation on Merck, which is supported by a Zacks #3 Rank (short-term “Hold” rating). Merck is currently facing issues like patent expirations of key drugs and EU pricing pressure. However, the company has a deep pipeline that should act as a cushion when its key products lose patent protection in the next few years.

Moreover, some of Merck's recent launches should start contributing significantly to the top line in the forthcoming quarters. The restructuring initiatives undertaken by the company should also improve its bottom line.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%